NIPPON SHINYAKU stock is traded under the ticker #4516. Below you can review NIPPON SHINYAKU stock performance in the past 12 months up to November 2025

Total visits to NIPPON SHINYAKU's top domains

Understand NIPPON SHINYAKU market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

nippon-shinyaku.co.jp120.4K

nspharma.com1.1K

See more with Sales Intelligence

Avg. visit duration in NIPPON SHINYAKU's top domains

Analyze NIPPON SHINYAKU engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

nippon-shinyaku.co.jp00:01:31

nspharma.com00:00:40

See more with Sales Intelligence

Avg. pageviews on NIPPON SHINYAKU's top domains

See how NIPPON SHINYAKU keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

nippon-shinyaku.co.jp3.07

nspharma.com1.57

See more with Sales Intelligence

NIPPON SHINYAKU top competitors by domain

Top similar sites in November 2025, ranked by their affinity

nippon-shinyaku-shop.comCompany NameNIPPON SHINYAKUEmployees1001 - 5000HQJapan, KyotoAnnual revenue> $1BTotal visits23.7KHealth > Biotechnology and Pharmaceuticals

Top technologies used by NIPPON SHINYAKU

These are the website technologies, by industry, used by NIPPON SHINYAKU top domains

Payment & Currencies (22)

PayPal

Advertising (6)

DoubleClick

Social (4)

Instagram

Mobile (2)

Meta Viewport

More Technologies

8

See all

News & Signals from NIPPON SHINYAKU

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsArisGlobal LLC signs new client Nippon Shinyaku.Nippon Shinyaku selects LifeSphere(R) Safety.

NewsNippon Shinyaku attends event World Muscle Society 2025 Congress.Brogidirsen (NS-089/NCNP-02) for the treatment of duchenne muscular dystrophy: 3.5-year clinical trial data presented at the World Muscle Society 2025 Congress.

NewsNippon Shinyaku is developing NS-051/NCNP-04.The designation was announced in a press release from NS Pharma, a subsidiary of Nippon Shinyaku, which is developing NS-051/NCNP-04.